Literature DB >> 1494770

Sex differences in hypokalaemic and electrocardiographic effects of inhaled terbutaline.

A R Rahman1, D G McDevitt, A D Struthers, B J Lipworth.   

Abstract

BACKGROUND: Gender differences in the chronotropic effects of infused isoprenaline have previously been described. The aim of the present study was to investigate possible gender differences in hypokalaemic, chronotropic, and electrocardiographic effects of inhaled terbutaline.
METHODS: Twenty healthy volunteers (10 female) were recruited (mean age 24 years for women (F) and 22 years for men (M). Subjects were given either inhaled terbutaline 5 mg or placebo in single blind, randomised crossover fashion and the following measurements were made for four hours after inhalation: (a) serum potassium concentration; (b) heart rate; (c) electrocardiographic sequelae (T wave amplitude, Q-Tc interval). The effects of terbutaline on serum potassium was chosen as the primary end point for detecting a 0.3 mmol/l difference between sexes, with a beta error of 0.2 and alpha set at 0.05.
RESULTS: The hypokalaemic effects of terbutaline were significantly greater in women, the potassium results (means and 95% CI) being as follows: lowest potassium concentration--F 3.12 (2.96-3.28) mmol/l v M 3.65 (3.49-3.81) mmol/l; percentage change from baseline at one hour--F 15.4% (11.5-19.3%) v M 8.5% (4.6-12.3%); average potassium concentration during the four hours--F 3.39 (3.33-3.46) mmol/l v M 3.78 (3.72-3.85) mmol/l. There was no significant regression between body weight and the potassium response to terbutaline. There were also significant sex differences for T wave, Q-Tc, and heart rate response. The percentage fall in T wave amplitude 30 minutes after terbutaline was: F 44.6% (32.1-57.0%) v M 22.4% (9.9-34.8%).
CONCLUSIONS: Women are more sensitive to the hypokalaemic, chronotropic, and electrocardiographic sequelae of inhaled terbutaline.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1494770      PMCID: PMC1021100          DOI: 10.1136/thx.47.12.1056

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

1.  Comparison of hypokalaemic, electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects.

Authors:  B J Lipworth; B F Tregaskis; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Systemic beta-adrenoceptor responses to salbutamol given by metered-dose inhaler alone and with pear shaped spacer attachment: comparison of electrocardiographic, hypokalaemic and haemodynamic effects.

Authors:  B J Lipworth; D G McDevitt; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

3.  Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta 2-adrenoceptor blockade.

Authors:  B J Lipworth; L C McFarlane; W J Coutie; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Adrenergic modulation of the delayed rectifier potassium channel in calf cardiac Purkinje fibers.

Authors:  P Bennett; L McKinney; T Begenisich; R S Kass
Journal:  Biophys J       Date:  1986-04       Impact factor: 4.033

5.  Influence of the menstrual cycle on airway function in asthmatic and normal subjects.

Authors:  B D Pauli; R L Reid; P W Munt; R D Wigle; L Forkert
Journal:  Am Rev Respir Dis       Date:  1989-08

6.  Asthma mortality in England and Wales: evidence for a further increase, 1974-84.

Authors:  P G Burney
Journal:  Lancet       Date:  1986-08-09       Impact factor: 79.321

7.  Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study.

Authors:  J Grainger; K Woodman; N Pearce; J Crane; C Burgess; A Keane; R Beasley
Journal:  Thorax       Date:  1991-02       Impact factor: 9.139

8.  Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study.

Authors:  J Crane; N Pearce; A Flatt; C Burgess; R Jackson; T Kwong; M Ball; R Beasley
Journal:  Lancet       Date:  1989-04-29       Impact factor: 79.321

Review 9.  Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?

Authors:  B J Lipworth; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

10.  The effects of cardioselective and non-selective beta-adrenoceptor blockade on the hypokalaemic and cardiovascular responses to adrenomedullary hormones in man.

Authors:  A D Struthers; J L Reid; R Whitesmith; J C Rodger
Journal:  Clin Sci (Lond)       Date:  1983-08       Impact factor: 6.124

View more
  6 in total

1.  Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device.

Authors:  D M Newnham; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  Age dependent systemic exposure to inhaled salbutamol.

Authors:  Klaus Bønnelykke; Jakob Jessing Jespersen; Hans Bisgaard
Journal:  Br J Clin Pharmacol       Date:  2007-03-01       Impact factor: 4.335

3.  Influence of sex-steroid hormones on the regulation of lymphocyte beta 2-adrenoceptors during the menstrual cycle.

Authors:  N M Wheeldon; D M Newnham; W J Coutie; J A Peters; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

Review 4.  Premenstrual asthma: epidemiology, pathogenesis and treatment.

Authors:  K S Tan
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Extrapulmonary beta 2-responses to intravenous salbutamol during the menstrual cycle.

Authors:  D M Newnham; N M Wheeldon; L C McFarlane; G A Clark; D G McDevitt; B J Lipworth
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Comparison of parameters of in vitro lymphocyte beta 2-adrenoceptor function in normal and asthmatic subjects.

Authors:  D M Newnham; W J Coutie; L C McFarlane; B J Lipworth
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.